NDAINTRAVENOUSSOLUTION
Approved
Oct 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
PARICALCITOL (paricalcitol) by Pfizer is synthetic, biologically active vitamin d 2 analog. Approved for secondary hyperparathyroidism, chronic kidney disease, end-stage renal disease. First approved in 2014.
Drug data last refreshed 20h ago
Mechanism of Action
synthetic, biologically active vitamin D 2 analog. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and…
Indications (3)
Worked on PARICALCITOL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.